Centrexion Therapeutics
PrivateLast Round
Debt
Dec 14, 2023
Total Funding Raised
$252.44M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Centrexion Therapeutics is a biopharmaceutical company that develops and commercializes non-opioid and non-addictive therapies for the treatment of chronic pain.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Centrexion Therapeutics Comparables
Compare Centrexion Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Latigo Biotherapeutics | 83% | |
| Eli Lilly and Company | 82% | |
| Akelos Inc. | 81% |
Centrexion Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Dec 14, 2023 | ||||
| Convertible Debt | Jul 11, 2023 | ||||
| Convertible Debt | Oct 29, 2020 | ||||
| Series D | Jan 2, 2018 | ||||
| Convertible Debt | Oct 10, 2017 | ||||
Convertible Debt | Apr 28, 2017 |
Centrexion Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| InterWest Partners | Convertible Debt, Series C, Series D, Series B, Series A |
| New Enterprise Associates | Convertible Debt, Series C, Series D, Series A, Series B |
| SLR Capital Partners | Convertible Debt |
| ArrowMark Partners | Convertible Debt, Series C, Series D |
| Efung Capital | Series D |
| 6 Dimensions Capital | Series D |
| Exome Asset Management | Convertible Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 63% MoM, reaching 2.4K.
- May 18, 2026
Monthly visitors increased 140% MoM, reaching 2.9K.
Centrexion Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Centrexion Therapeutics's valuation, stock price, and market status.
Is Centrexion Therapeutics a public or private company?
Centrexion Therapeutics is a private company.
What is the current stock price of Centrexion Therapeutics?
Centrexion Therapeutics is a private company, so its shares have no public market price. Caplight tracks Centrexion Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Centrexion Therapeutics worth (valuation)?
Valuation information for Centrexion Therapeutics is not publicly available.
Can I buy Centrexion Therapeutics stock?
Centrexion Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Centrexion Therapeutics's last funding round?
Centrexion Therapeutics's most recent funding round was Debt on December 14, 2023.
Who are the main investors in Centrexion Therapeutics?
Key investors in Centrexion Therapeutics include InterWest Partners.
Will Centrexion Therapeutics IPO soon?
No public IPO plans have been announced for Centrexion Therapeutics.
How can I track Centrexion Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Centrexion Therapeutics's shares on secondary markets.